Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1106089 | 0.83 | CA2 (0.33) | CA2 | |
| SCHEMBL18235546 | 0.77 | CA2 (0.30) | CA2 | |
| SCHEMBL24684889 | 0.74 | NPC1 (0.32) | — | |
| SCHEMBL27841857 | 0.70 | — | — | |
| SCHEMBL802241 | 0.69 | KDM4E (0.38) | CA2 | |
| SCHEMBL18235325 | 0.68 | — | — | |
| SCHEMBL16682774 | 0.67 | CA2 (0.42) | CA2 | |
| SCHEMBL27907887 | 0.67 | CA2 (0.32) | CA2 | |
| SCHEMBL24499191 | 0.65 | MAPT (0.32) | — | |
| SCHEMBL9937995 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912680-B2 | Nitric oxide releasing prodrugs of MDA and MDMA | EMPATHBIO, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230227421-A1 | NITRIC OXIDE RELEASING PRODRUGS OF MDA AND MDMA | JMD PHARMA CREATIVITY, LLC | 2023-07-20 | — | — | US | disclosed |
| WO-2022067100-A2 | PLK1 POLO BOX DOMAIN INHIBITOR AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227421-A1 | NITRIC OXIDE RELEASING PRODRUGS OF MDA AND MDMA | NOS1, NOS3, NOS2 | CA2 4040/4885 |
| US-11912680-B2 | Nitric oxide releasing prodrugs of MDA and MDMA | NOS1, NOS3, NOS2 | CA2 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.